Longevity Drugs for Dogs, PFAS Detox, and Gene Therapies | Longevity News Roundup — Week 7, 2026

Sponsor: StrideStride helps people understand and improve their wellbeing and longevity through personalised DNA, microbiome, blood biomarker testing, expert guidance, tailored supplements, and actionable insights grounded in robust human science. Click the link below to learn more and use the code 'UNLOCKED' for your 10% discount. Link: https://www.getstride.com/unlocked/______________________In this week’s Longevity News Roundup, Phil Newman and Dr. Nina Patrick explore breakthroughs shaping healthspan and longevity, from pioneering longevity drugs for dogs to one-shot gene therapies for ALS, AI-driven longevity data platforms, and innovations in environmental detox.Loyal, backed by Laura Deming’s Age1 Fund and other investors, raised $100 million Series C to advance LOY002, a daily pill aimed at extending the healthy lifespan of senior dogs. The drug has cleared two of three FDA hurdles, and its STAY trial will enroll 1,300 dogs across 70 clinics, potentially setting a regulatory precedent for aging as an approvable indication.Decoding Longevity Trends, a new AI-native platform tracking over 600 longevity-focused companies, including pipelines, mechanisms of action, and clinical stages. The system features a chatbot for complex queries and aims to accelerate insights for investors, pharma, and operators in the longevity ecosystem.Cambiotics, a Copenhagen-based startup, raised $4 million to develop 46and, a probiotic supplement designed to help the body eliminate PFAS (“forever chemicals”). Early research shows specific gut bacteria can bind PFAS, with human trials expected in the US this year, marking a step forward in exposome-based longevity interventions.In neurodegeneration news, Vector Y dosed its first patient in a Phase 1 trial for VTX002, a one-time gene therapy targeting TDP43 pathology in ALS. This vectorized antibody approach installs a long-term antibody factory in the CNS, potentially transforming treatment from repeated dosing to durable, one-shot interventions and extending to other neurodegenerative conditions.The biohacking and self-managed health sector is projected to hit $216 billion by 2035, led by North America. Wearables, diagnostics, genetics, and personalized health platforms are driving adoption, while longevity and neuroscience increasingly intersect with consumer-driven biohacking practices.Backed by a five-year, $3.3 million federal award, a new research initiative at Oregon Health & Science University (OHSU) aims to develop a retinal screening tool that could flag the earliest biological signals of Alzheimer’s using nothing more than an eye drop and a quick scan.______________________News & References:Loyal raises $100m as canine longevity drug nears approval → https://longevity.technology/news/loyal-raises-100m-as-canine-longevity-drug-nears-approval/VectorY doses first patient in ALS gene therapy trial → https://longevity.technology/news/vectory-doses-first-patient-in-als-gene-therapy-trial/Longevity.Technology unveils DLT – the intelligence platform for longevity → https://longevity.technology/news/longevity-technology-unveils-dlt-the-intelligence-platform-for-longevityDanish startup aims to remove ‘forever chemicals’ from the body → https://longevity.technology/news/danish-startup-aims-to-remove-forever-chemicals-from-the-body/Biohacking market projected to top US$216 billion by 2035 → https://longevity.technology/news/biohacking-market-projected-to-top-us216-billion-by-2035/New retinal screening targets Alzheimer’s before memory loss → https://longevity.technology/news/new-retinal-screening-targets-alzheimers-before-memory-loss/______________________Hosts:Phil Newman: ⁠⁠https://qrco.de/bgXpNY⁠⁠Nina Patrick: ⁠⁠https://qrco.de/bgXpKn⁠⁠